The therapeutic panorama of multiple myeloma is changing in frontline treatment. The quadruplets are showing wonderful results, in particular, in terms of a progression-free survival, but also in MRD-negativity, not paying on quality of life for our patients. And they think that this is the present, the next future, that daratumumab is becoming the new backbone in transplant-eligible and not eligible patients...
The therapeutic panorama of multiple myeloma is changing in frontline treatment. The quadruplets are showing wonderful results, in particular, in terms of a progression-free survival, but also in MRD-negativity, not paying on quality of life for our patients. And they think that this is the present, the next future, that daratumumab is becoming the new backbone in transplant-eligible and not eligible patients. And I think that this is the biggest novelties of last year.
Moreover in relapsed and refractory setting, we are seeing many wonderful novel agents such as the selinexor, belantamab, but also melflufen and other drugs which are increasing their results. And they think that we are going toward the new combination, so with great results in terms of survival, but also in terms of deepness of response, and this is a wonderful achievement in so difficult to treat patients.
It is also the word over CAR-T and cellular therapies. I think that at the moment, that they are only for patients where we feel at that, the current available opportunities. But I think that considering the results, so we are seeing from clinical trials, maybe they will be anticipated as soon as possible.
I think that immunotherapy is the present and the future of multiple myeloma. And I think that, some years ago we spoke about the difficulty to treat multiple myeloma. But I think that, now we are going toward a new change of a scenario which we can write, I hope as soon as possible, the term ‘cure’ for our multiple myeloma patients.